Isomorphic Labs Raises $5 Billion Series C Led by Greenoaks and Sequoia Six Months After $2.1 Billion Round
The DeepMind spinout run by Demis Hassabis has no drug in the clinic yet, but investors are funding its AI design engine and clinical build-out at record scale.

Key facts
- Isomorphic Labs announced a $5bn Series C co-led by Greenoaks and Sequoia Capital on 17 November 2026, about six months after a $2.1bn round.[1][2]
- Isomorphic Labs has raised more than $7.7bn in total since its 2021 founding, according to Pharmaphorum.[3][4]
- Isomorphic Labs has not disclosed a valuation; Bloomberg reported earlier that the round was being discussed at roughly $50bn.[1][4]
- Isomorphic Labs reports positive preclinical results in oncology and immunology with Eli Lilly, Novartis and Johnson & Johnson as partners, but no candidate has entered clinical trials.[3][1]
- Demis Hassabis said in January he expected first clinical trials by the end of 2026 but gave Bloomberg no updated target, according to The Next Web.[1]
Isomorphic Labs, the London-based AI drug-design company spun out of Google DeepMind, announced on 17 November 2026 a $5bn Series C co-led by Greenoaks and Sequoia Capital, about six months after a $2.1bn round in May. The company has not put a drug into the clinic, and it did not disclose a valuation; Bloomberg reported earlier that the round was being discussed at roughly $50bn.
The size of the cheque is the story. The Next Web reported that the round was oversubscribed and that new investors include Andreessen Horowitz alongside Alphabet, which continued significant investment. Existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part. Pharmaphorum put total money raised since the company's 2021 founding at more than $7.7bn.
What is the money for?
Tech.eu said the proceeds will support AI development and clinical development infrastructure and advance drug candidates toward clinical trials. Pharmaphorum added that the company intends to build foundational simulation models, move internal and partnered medicine candidates forward and expand its AI-driven bioengineering infrastructure.
The platform at the centre of that plan is IsoDDE, Isomorphic's drug design engine. Pharmaphorum described it as built on AI models that predict three-dimensional protein structures, drug-target interactions and binding affinities, and that identify new binding pockets. It builds on AlphaFold, the DeepMind system for predicting protein structures, according to The Next Web, which said the company was founded in 2021 to build on that work.
Chief executive Demis Hassabis told Bloomberg, as relayed by The Next Web, that the aim is "a platform to do hundreds of drugs a year", and that the company will expand beyond small molecules into "pretty much all modalities", including large-molecule biologics. Tech.eu quoted him saying the engine is "generating molecules with unprecedented precision and speed."
OfficeChai described IsoDDE as a set of simulation models supported by in-house AI agents, and listed the planned uses of the money as scaling that engine, building the pipeline of AI-designed candidates, developing a partner ecosystem around disease biology, building global AI-led bioengineering infrastructure and adding AI-first translational and clinical development capabilities. That last item is the tell: the company is building the machinery to run trials, not only to design molecules.
How far along is the science?
Isomorphic says its preclinical results are positive in oncology and immunology, both in its own programmes and with partners. Pharmaphorum named the partners as Eli Lilly, Novartis and Johnson & Johnson. The Next Web reported Hassabis saying that more than 20 programmes are under way.
Clinical entry is the milestone still missing. The Next Web wrote that Hassabis said in January he expected the first clinical trials by the end of 2026, but he gave Bloomberg no updated target, saying the company is on track with regulatory submissions and will have more to announce in 2027. Pharmaphorum likewise reported that no candidates have entered trials and that no dates were given. The Next Web also noted that no regulator has yet approved an AI-designed drug.
Why does the round matter?
Three features stand out. First, the pace. OfficeChai listed the funding history: a $600m first external round led by Thrive Capital in March 2025, a $2.1bn Series B led by Thrive in May 2026, and now the $5bn Series C. By those figures, $7.1bn of the roughly $7.7bn raised from outside investors arrived within about eight months. Second, the investor mix. Growth-stage technology investors such as Sequoia and Greenoaks are leading a biotech round, and The Next Web reported that Sequoia cited scaling laws, the observation that model performance improves with more compute and data, as part of its case. Konstantine Buhler of Sequoia said Isomorphic "is building foundational technology for the future of medicine." OfficeChai quoted Greenoaks' Neil Mehta describing drug discovery as "an optimization challenge of almost infinite scale", and Isomorphic president Max Jaderberg saying, "Every week we are making repeatable scientific advancements enabled by our models."
Third, the capital is a bet on compute as much as chemistry. Tech.eu said a portion of the proceeds funds computing infrastructure, and Pharmaphorum said the round also boosted UK biotech and venture financing in 2026, though Isomorphic accounts for most of the total. Asked about compute, Hassabis told Bloomberg, "We've got very secure compute pipelines", according to The Next Web, which noted the details of those arrangements were not disclosed.
Who is steering the company?
The Next Web reported that Hassabis stepped back as DeepMind chief executive in August and is now DeepMind's chair and Alphabet's chief scientist, while remaining Isomorphic's chief executive. Tech.eu and OfficeChai identified Max Jaderberg as president. Isomorphic is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, according to The Next Web.
What we don't know yet
Several material facts are unconfirmed. The valuation is not official: the roughly $50bn figure comes from Bloomberg's earlier reporting, and Pharmaphorum describes it as an estimated paper value. Individual investor contributions and the round's full terms were not disclosed, nor were the financial terms of the pharma partnerships. The sources also differ in labelling: Tech.eu calls the May round a Series B, while Pharmaphorum calls it a second round. The timing of the first clinical trial is the open question that will matter most.
If Isomorphic reaches the clinic in 2027 with candidates designed largely by its models, the funding will look like a down payment on a new way to run drug discovery. If it slips, the round will still have bought the company something rare in biotech: years of runway and a large compute budget with which to keep trying. Either way, a $5bn cheque for a company with no drug in human trials marks how much investors now treat AI-native drug discovery as an infrastructure bet.




